NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis $17.72 -0.23 (-1.28%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$17.41▼$17.9950-Day Range$10.25▼$17.9552-Week Range$6.07▼$18.58Volume1.11 million shsAverage Volume761,461 shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$22.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Phathom Pharmaceuticals alerts: Email Address Phathom Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside27.0% Upside$22.50 Price TargetShort InterestBearish24.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 5 Articles This WeekInsider TradingSelling Shares$575,147 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.57) to ($4.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.98 out of 5 starsMedical Sector543rd out of 910 stocksPharmaceutical Preparations Industry251st out of 426 stocks 3.4 Analyst's Opinion Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePhathom Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Phathom Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted24.34% of the outstanding shares of Phathom Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 20.4, which indicates bearish sentiment.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently increased by 3.79%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHAT. Previous Next 2.3 News and Social Media Coverage News SentimentPhathom Pharmaceuticals has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest9 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $575,147.00 in company stock.Percentage Held by Insiders24.10% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phathom Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($5.57) to ($4.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Phathom Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Mode MobilePre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.Claim Exclusive 100% Bonus: $0.25/Share About Phathom Pharmaceuticals Stock (NASDAQ:PHAT)Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Read More PHAT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHAT Stock News HeadlinesSeptember 7 at 8:31 AM | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Sets New 52-Week High at $17.25September 1, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Rating Reiterated by Needham & Company LLCSeptember 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 30, 2024 | markets.businessinsider.comPhathom Pharmaceuticals’ V oquezna Shows Promising Market Penetration and Drives Buy RatingAugust 30, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Hits New 52-Week High at $15.84August 29, 2024 | globenewswire.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 23, 2024 | markets.businessinsider.comPhathom Pharmaceuticals’ V oquezna: A Rising Star in GERD Treatment MarketAugust 19, 2024 | globenewswire.comPhathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded WarrantsSeptember 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 17, 2024 | finance.yahoo.comPHAT Sep 2024 5.000 call (PHAT240920C00005000)August 15, 2024 | msn.comThis New Drug for GERD Works Better Than Proton Pump InhibitorsAugust 12, 2024 | msn.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.comPhathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | markets.businessinsider.comMaintaining Hold on Phathom Pharmaceuticals Amidst Modest Voquezna Sales UptickAugust 8, 2024 | markets.businessinsider.comPHAT Stock Earnings: Phathom Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024August 8, 2024 | markets.businessinsider.comPhathom Pharmaceuticals Outperforms with Voquezna Driving Revenue Growth: Buy Rating ReaffirmedAugust 8, 2024 | msn.comPhathom Pharmaceuticals Non-GAAP EPS of -$1.25, revenue of $7.3MAugust 8, 2024 | globenewswire.comPhathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateSee More Headlines Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHAT CUSIPN/A CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$22.50 High Stock Price Target$28.00 Low Stock Price Target$12.00 Potential Upside/Downside+27.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-201,590,000.00 Net MarginsN/A Pretax Margin-2,995.67% Return on EquityN/A Return on Assets-75.81% Debt Debt-to-Equity RatioN/A Current Ratio6.48 Quick Ratio6.44 Sales & Book Value Annual Sales$9.92 million Price / Sales104.58 Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-13.95Miscellaneous Outstanding Shares58,535,000Free Float44,428,000Market Cap$1.04 billion OptionableOptionable Beta0.71 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Terrie J. Curran (Age 55)President, CEO & Director Comp: $1.22MMr. David A. Socks (Age 49)Co-Founder & Director Comp: $54.17kDr. Azmi Nabulsi M.D. (Age 64)M.P.H., Co-Founder & COO Comp: $888.9kMs. Molly Henderson CPA (Age 53)MBA, Chief Financial & Business Officer Comp: $777.76kDr. Aditya Kohli Ph.D. (Age 36)Co-Founder Comp: $319.65kMr. Paul CocjaChief People OfficerMr. Tom HarrisChief Development Sciences OfficerDr. Eckhard Leifke M.D.Ph.D., Chief Medical OfficerMr. Martin J. GilliganChief Commercial OfficerMore ExecutivesKey CompetitorsInnovivaNASDAQ:INVAORIC PharmaceuticalsNASDAQ:ORICArcutis BiotherapeuticsNASDAQ:ARQTOcular TherapeutixNASDAQ:OCULNkartaNASDAQ:NKTXView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPSold 19,500 shares on 8/16/2024Ownership: 0.000%Creative PlanningSold 5,151 shares on 8/16/2024Ownership: 0.045%The Manufacturers Life Insurance Company Bought 1,339 shares on 8/15/2024Ownership: 0.023%Oracle Investment Management Inc.Bought 225,000 shares on 8/14/2024Ownership: 0.378%Marshall Wace LLPBought 112,691 shares on 8/14/2024Ownership: 0.193%View All Insider TransactionsView All Institutional Transactions PHAT Stock Analysis - Frequently Asked Questions How have PHAT shares performed this year? Phathom Pharmaceuticals' stock was trading at $9.13 on January 1st, 2024. Since then, PHAT shares have increased by 94.1% and is now trading at $17.72. View the best growth stocks for 2024 here. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) released its earnings results on Thursday, August, 8th. The company reported ($1.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.39) by $0.04. The business had revenue of $7.32 million for the quarter, compared to analysts' expectations of $5.65 million. When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 7,900,000 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Phathom Pharmaceuticals' major shareholders? Phathom Pharmaceuticals' top institutional investors include Ensign Peak Advisors Inc (3.84%), Oracle Investment Management Inc. (0.38%), Bank of New York Mellon Corp (0.20%) and Marshall Wace LLP (0.19%). Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Terrie Curran, Azmi Nabulsi, Asit Parikh and David A Socks. View institutional ownership trends. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK) and CenterPoint Energy (CNP). This page (NASDAQ:PHAT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
